Cargando…
Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity
Passive immunization against TNF allowed non-tumor-bearing C3H/HEN mice and tumor-bearing C57BL/6 mice to tolerate significantly more doses of IL-2 before death (p less than 0.005 and p less than 0.001, respectively). The antitumor effect of IL-2 against both 3-d and 10-d pulmonary metastases was ma...
Formato: | Texto |
---|---|
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
1989
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2189429/ https://www.ncbi.nlm.nih.gov/pubmed/2788701 |
_version_ | 1782146640189063168 |
---|---|
collection | PubMed |
description | Passive immunization against TNF allowed non-tumor-bearing C3H/HEN mice and tumor-bearing C57BL/6 mice to tolerate significantly more doses of IL-2 before death (p less than 0.005 and p less than 0.001, respectively). The antitumor effect of IL-2 against both 3-d and 10-d pulmonary metastases was maintained in mice treated concurrently with neutralizing antibodies to TNF. In one experiment with 10-d pulmonary metastases, increased administration of IL-2 made possible by passive immunization against TNF significantly improved the antitumor response compared to equitoxic doses of IL-2 and control antibody. The results indicate that TNF is a mediator of IL-2 toxicity but contributes minimally to the antitumor effects of IL-2. Strategies to inhibit TNF may improve the therapeutic index of IL-2 as a neoplastic agent. |
format | Text |
id | pubmed-2189429 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1989 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-21894292008-04-17 Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity J Exp Med Articles Passive immunization against TNF allowed non-tumor-bearing C3H/HEN mice and tumor-bearing C57BL/6 mice to tolerate significantly more doses of IL-2 before death (p less than 0.005 and p less than 0.001, respectively). The antitumor effect of IL-2 against both 3-d and 10-d pulmonary metastases was maintained in mice treated concurrently with neutralizing antibodies to TNF. In one experiment with 10-d pulmonary metastases, increased administration of IL-2 made possible by passive immunization against TNF significantly improved the antitumor response compared to equitoxic doses of IL-2 and control antibody. The results indicate that TNF is a mediator of IL-2 toxicity but contributes minimally to the antitumor effects of IL-2. Strategies to inhibit TNF may improve the therapeutic index of IL-2 as a neoplastic agent. The Rockefeller University Press 1989-09-01 /pmc/articles/PMC2189429/ /pubmed/2788701 Text en This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Articles Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity |
title | Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity |
title_full | Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity |
title_fullStr | Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity |
title_full_unstemmed | Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity |
title_short | Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity |
title_sort | passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2189429/ https://www.ncbi.nlm.nih.gov/pubmed/2788701 |